SOCS4

Summary

SOCS4 (suppressor of cytokine signaling 4, HGNC:19392) is a protein-coding gene on chromosome 14q22.3, encoding Suppressor of cytokine signaling 4 (Q8WXH5). SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction.

The protein encoded by this gene contains a SH2 domain and a SOCS BOX domain. The protein thus belongs to the suppressor of cytokine signaling (SOCS), also known as STAT-induced STAT inhibitor (SSI), protein family. SOCS family members are known to be cytokine-inducible negative regulators of cytokine signaling. Two alternatively spliced transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 122809 — RefSeq curated summary.

At a glance

• Gene–disease (curated): autoimmune disease (Limited, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 142 total
• MANE Select transcript: NM_199421

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19392
Approved symbol	SOCS4
Name	suppressor of cytokine signaling 4
Location	14q22.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000180008
Ensembl biotype	protein_coding
OMIM	616337
Entrez	122809

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 12 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000339298, ENST00000395472, ENST00000553735, ENST00000555846, ENST00000891272, ENST00000891273, ENST00000891274, ENST00000891275, ENST00000891276, ENST00000922082, ENST00000922083, ENST00000922084, ENST00000922085

RefSeq mRNA: 2 — MANE Select: NM_199421 NM_080867, NM_199421

CCDS: CCDS9722

Canonical transcript exons

ENST00000555846 — 3 exons

Exon	Start	End
ENSE00001335005	55027236	55027471
ENSE00001383269	55031863	55031991
ENSE00002524499	55042952	55049489

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 95.36.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4244 / max 75.2563, expressed in 713 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139683	15.7037	1769
139682	0.6106	344
139684	0.2311	106
139681	0.1907	73
139685	0.1902	83
139686	0.1754	71
139687	0.0264	15

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	95.36	gold quality
tibia	UBERON:0000979	92.17	gold quality
visceral pleura	UBERON:0002401	91.75	gold quality
parietal pleura	UBERON:0002400	89.62	gold quality
cauda epididymis	UBERON:0004360	89.18	gold quality
germinal epithelium of ovary	UBERON:0001304	89.10	gold quality
ileal mucosa	UBERON:0000331	88.93	gold quality
mucosa of paranasal sinus	UBERON:0005030	88.73	gold quality
cardiac muscle of right atrium	UBERON:0003379	88.70	silver quality
tibialis anterior	UBERON:0001385	88.30	silver quality
left ventricle myocardium	UBERON:0006566	88.17	silver quality
caput epididymis	UBERON:0004358	88.04	gold quality
oviduct epithelium	UBERON:0004804	87.89	gold quality
skin of hip	UBERON:0001554	87.51	gold quality
palpebral conjunctiva	UBERON:0001812	87.36	gold quality
colonic epithelium	UBERON:0000397	87.35	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.04	gold quality
epithelium of nasopharynx	UBERON:0001951	86.79	gold quality
secondary oocyte	CL:0000655	86.78	gold quality
thymus	UBERON:0002370	86.78	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.60	gold quality
superficial temporal artery	UBERON:0001614	86.35	gold quality
bronchial epithelial cell	CL:0002328	86.12	gold quality
mucosa of sigmoid colon	UBERON:0004993	86.02	gold quality
lower lobe of lung	UBERON:0008949	85.93	gold quality
myocardium	UBERON:0002349	85.90	silver quality
corpus epididymis	UBERON:0004359	85.86	gold quality
kidney epithelium	UBERON:0004819	85.86	gold quality
bronchus	UBERON:0002185	85.68	gold quality
heart right ventricle	UBERON:0002080	85.12	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.30

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RUNX1, STAT1

miRNA regulators (miRDB)

245 targeting SOCS4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-568	99.98	69.86	2084
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790

Literature-anchored findings (GeneRIF, showing 14)

• the expression of SOCS5 and its closest homolog SOCS4 is elevated in cells following treatment with EGF, similar to several negative feedback regulators of EGFR whose expression is up-regulated upon receptor activation. (PMID:15590694)
• The structure of the SOCS4-ElonginC-ElonginB complex reveals a distinct SOCS structural class. (PMID:17997974)
• Higher mRNA expression levels of SOCS1, 3, 4 and 7 are significantly associated with earlier tumour stage and better clinical outcome in human breast cancer. (PMID:20433750)
• These data suggest that miRNAs play an important role in the regulation of cytokine-inducible Src homology and SOCS expression in epithelial cells in response to C. parvum infection. (PMID:20486857)
• The expression of SOCS4 seems to be controlled epigenetically and is often weakly expressed in gastric cancer tissue and cell lines. SOCS4 methylation status could be a predictor of gastric cancer prognosis. (PMID:22127425)
• Identified is a conserved region of about 70 residues in the N-terminal domains of SOCS4 and 5 that is predicted to be more ordered than the surrounding sequence. (PMID:22423360)
• This study showed that increased protein levels of SOCS-4 and SOCS-7 in Alzheimer’s disease brains. (PMID:25286386)
• SOCS4 is a known inhibitor of epidermal growth factor (EGF) receptor signalling, and functional studies demonstrated specific upregulation of EGF-dependent immune stimulation in affected family members. (PMID:25639832)
• miR-25 promotes the migration and invasion of thyroid cancer cells by directly binding to the 3’-UTR of SOCS4 that leads to the inhibition of SOCS4. (PMID:26437444)
• Significantly higher levels of suppressor of cytokine signalling proteins SOCS3 and SOCS4 in non-healing chronic wounds compared to the healing/healed chronic wounds were observed at the transcript level. (PMID:27635428)
• In vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing have been presented. (PMID:28751715)
• Mechanistic investigations demonstrated that TUSC7 can interact with miR-616 and decrease its expression, thereby upregulating the expression of miR-616’s targets SOCS4 (SOCS5). (PMID:31200002)
• SOCS4 expression was lower in T-cell-mediated kidney allograft rejection group compared with non-rejected individuals (PMID:31398463)
• Exosome-mediated miR-9-5p promotes proliferation and migration of renal cancer cells both in vitro and in vivo by targeting SOCS4. (PMID:32819588)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	socs4	ENSDARG00000078509
danio_rerio	socs1b	ENSDARG00000089873
mus_musculus	Socs4	ENSMUSG00000048379
rattus_norvegicus	Socs4	ENSRNOG00000068183
drosophila_melanogaster	Socs44A	FBGN0033266
drosophila_melanogaster	Socs36E	FBGN0041184

Paralogs (7): CISH (ENSG00000114737), SOCS2 (ENSG00000120833), SOCS6 (ENSG00000170677), SOCS5 (ENSG00000171150), SOCS3 (ENSG00000184557), SOCS1 (ENSG00000185338), SOCS7 (ENSG00000274211)

Protein

Protein identifiers

Suppressor of cytokine signaling 4 — Q8WXH5 (reviewed: Q8WXH5)

Alternative names: Suppressor of cytokine signaling 7

All UniProt accessions (2): Q8WXH5, Q5H9R6

UniProt curated annotations — full annotation on UniProt →

Function. SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. Substrate-recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Inhibits EGF signaling by mediating the degradation of the Tyr-phosphorylated EGF receptor/EGFR.

Domain organisation. The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.

Induction. Up-regulated by EGF.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (2): NP_543143, NP_955453* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR001496	SOCS_box	Domain
IPR022252	SOCS4/SOCS5_dom	Domain
IPR035864	SOCS4_SH2	Domain
IPR036036	SOCS_box-like_dom_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR037342	SOCS4_SOCS	Domain

Pfam: PF00017, PF07525, PF12610

UniProt features (22 total): strand 9, helix 7, domain 2, compositionally biased region 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2IZV	X-RAY DIFFRACTION	2.55

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WXH5-F1	65.73	0.33

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-8939242	RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-8878171	Transcriptional regulation by RUNX1

MSigDB gene sets: 344 (showing top): AGGAAGC_MIR5163P, GOBP_REGULATION_OF_PROTEIN_TYROSINE_KINASE_ACTIVITY, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, ACTACCT_MIR196A_MIR196B, GOBP_NEGATIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GCM_GSPT1, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_NEGATIVE_REGULATION_OF_KINASE_ACTIVITY, GOBP_RESPONSE_TO_PEPTIDE, MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, RORA1_01, GOBP_NEGATIVE_REGULATION_OF_ERBB_SIGNALING_PATHWAY

GO Biological Process (6): negative regulation of epidermal growth factor-activated receptor activity (GO:0007175), protein ubiquitination (GO:0016567), cytokine-mediated signaling pathway (GO:0019221), positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436), intracellular signal transduction (GO:0035556), negative regulation of signal transduction (GO:0009968)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Transcriptional regulation by RUNX1	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	2
epidermal growth factor receptor activity	1
negative regulation of epidermal growth factor receptor signaling pathway	1
negative regulation of protein tyrosine kinase activity	1
negative regulation of signaling receptor activity	1
protein modification by small protein conjugation	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
regulation of proteasomal ubiquitin-dependent protein catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
positive regulation of proteasomal protein catabolic process	1
positive regulation of ubiquitin-dependent protein catabolic process	1
intracellular anatomical structure	1
regulation of signal transduction	1
negative regulation of cell communication	1
negative regulation of signaling	1
negative regulation of response to stimulus	1
binding	1

Protein interactions and networks

STRING

992 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SOCS4	ELOB	Q15370	819
SOCS4	ELOC	Q15369	814
SOCS4	CUL5	Q93034	797
SOCS4	SEPTIN6	Q14141	781
SOCS4	NCK1	P16333	779
SOCS4	SEPTIN7	Q16181	775
SOCS4	RNF7	Q9UBF6	729
SOCS4	IRS4	O14654	709
SOCS4	H3BTC1	H3BTC1	700
SOCS4	JAK1	P23458	606
SOCS4	ASB9	Q96DX5	604
SOCS4	EGFR	P00533	603
SOCS4	SOCS5	O75159	593
SOCS4	SEPTIN11	Q9NVA2	589
SOCS4	SEPTIN8	Q92599	587

IntAct

83 interactions, top by confidence:

A	B	Type	Score
CUL5	SOCS2	psi-mi:“MI:0914”(association)	0.880
ELOC	ELOB	psi-mi:“MI:0915”(physical association)	0.740
CUL5	SOCS7	psi-mi:“MI:0914”(association)	0.640
SOCS4	PINK1	psi-mi:“MI:0915”(physical association)	0.570
SOCS4	RBP7	psi-mi:“MI:0915”(physical association)	0.570
PIK3R3	SOCS4	psi-mi:“MI:0915”(physical association)	0.570
GRB2	SOCS4	psi-mi:“MI:0915”(physical association)	0.570
SOCS4	GRB2	psi-mi:“MI:0915”(physical association)	0.570
RBP7	SOCS4	psi-mi:“MI:0915”(physical association)	0.570
SOCS4	PIK3R3	psi-mi:“MI:0915”(physical association)	0.570
TEKT4	SOCS4	psi-mi:“MI:0915”(physical association)	0.560
SOCS4	DMWD	psi-mi:“MI:0915”(physical association)	0.560
SOCS4		psi-mi:“MI:0915”(physical association)	0.560
SOCS4	GARS1	psi-mi:“MI:0915”(physical association)	0.560
SOCS4	SPTLC1	psi-mi:“MI:0915”(physical association)	0.560
SOCS4	BSCL2	psi-mi:“MI:0915”(physical association)	0.560
SOCS4	HTRA2	psi-mi:“MI:0915”(physical association)	0.560
SOCS4	JPH3	psi-mi:“MI:0915”(physical association)	0.560
SOCS4	PANK2	psi-mi:“MI:0915”(physical association)	0.560
SOCS4	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
HTT	SOCS4	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (35): SOCS4 (Two-hybrid), SOCS4 (Two-hybrid), PPAPDC2 (Two-hybrid), LDHAL6B (Two-hybrid), LECT1 (Two-hybrid), MPP5 (Two-hybrid), PINK1 (Two-hybrid), RBP7 (Two-hybrid), TNK2 (Two-hybrid), SOCS4 (Two-hybrid), FRS3 (Affinity Capture-Luminescence), GRB2 (Affinity Capture-Luminescence), PIK3R3 (Affinity Capture-Luminescence), PINK1 (Affinity Capture-Luminescence), RBP7 (Affinity Capture-Luminescence)

ESM2 similar proteins: A0A0G2JUG7, A6H8H5, A7XYJ6, A8T6P4, B2RWW0, E1BE02, O08774, O14544, O14924, O54928, O75159, P42335, P59808, Q08D35, Q0VC91, Q13009, Q29RN6, Q4ZHA6, Q56A36, Q5DTV4, Q5HYM0, Q5RCM6, Q5RDX2, Q5SSZ5, Q5SW75, Q5ZJ69, Q60610, Q63099, Q6IRU7, Q6P0Q8, Q6P1H6, Q6S5L8, Q6S7F2, Q6ZPI0, Q76I79, Q76N89, Q7TP65, Q811L6, Q8C115, Q8K4P8

Diamond homologs: O00459, O08908, O14508, O14512, O14543, O14544, O15524, O35716, O35717, O35718, O46404, O54928, O55033, O70512, O75159, O88582, O88583, P23726, P23727, P26450, P27986, Q0VC91, Q29RN6, Q2HJ53, Q54RB7, Q5R685, Q5RCM6, Q5RDX2, Q62225, Q63787, Q63788, Q63789, Q64143, Q68AM8, Q7YRV6, Q861R0, Q8UUU2, Q8VHQ2, Q8WXH5, Q90X67

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
SOCS4	“down-regulates quantity by destabilization”	DAB1	binding
SOCS4	“up-regulates activity”	CUL5	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 32 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Neddylation	5	9.9×	6e-03

GO biological processes:

GO term	Partners	Fold	FDR
protein ubiquitination	7	9.7×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

142 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	124
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1883 predictions. Top by Δscore:

Variant	Effect	Δscore
17:38352644:G:GT	donor_gain	1.0000
17:38361702:A:AG	acceptor_gain	1.0000
17:38361703:C:G	acceptor_gain	1.0000
17:38361707:CTAG:C	acceptor_loss	1.0000
17:38361709:AGG:A	acceptor_loss	1.0000
17:38366282:TGCA:T	acceptor_loss	1.0000
17:38366284:CA:C	acceptor_loss	1.0000
17:38366285:A:AG	acceptor_gain	1.0000
17:38366285:AGAT:A	acceptor_gain	1.0000
17:38366286:G:GC	acceptor_gain	1.0000
17:38366286:GA:G	acceptor_gain	1.0000
17:38366286:GAT:G	acceptor_gain	1.0000
17:38366286:GATG:G	acceptor_gain	1.0000
17:38366286:GATGC:G	acceptor_gain	1.0000
17:38366414:GAAG:G	donor_gain	1.0000
17:38366417:GGTA:G	donor_loss	1.0000
17:38366419:T:G	donor_loss	1.0000
17:38367880:A:AG	acceptor_gain	1.0000
17:38367880:AGTGT:A	acceptor_gain	1.0000
17:38367881:G:GG	acceptor_gain	1.0000
17:38367881:GT:G	acceptor_gain	1.0000
17:38367881:GTGTG:G	acceptor_gain	1.0000
17:38377808:A:T	donor_gain	1.0000
17:38395439:GCC:G	donor_gain	1.0000
17:38395441:C:CG	donor_gain	1.0000
17:38395441:C:G	donor_gain	1.0000
17:38395445:G:GG	donor_gain	1.0000
17:38361693:T:TA	acceptor_gain	0.9900
17:38361709:A:AG	acceptor_gain	0.9900
17:38361709:AG:A	acceptor_gain	0.9900

AlphaMissense

2940 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:55043435:T:C	C132R	1.000
14:55043471:T:A	W144R	1.000
14:55043471:T:C	W144R	1.000
14:55043473:G:C	W144C	1.000
14:55043473:G:T	W144C	1.000
14:55043903:T:A	W288R	1.000
14:55043903:T:C	W288R	1.000
14:55043905:G:C	W288C	1.000
14:55043905:G:T	W288C	1.000
14:55043906:G:A	G289R	1.000
14:55043906:G:C	G289R	1.000
14:55043907:G:A	G289E	1.000
14:55043907:G:T	G289V	1.000
14:55043916:A:T	D292V	1.000
14:55043928:C:A	A296D	1.000
14:55043940:T:A	L300Q	1.000
14:55043940:T:C	L300P	1.000
14:55043957:G:C	G306R	1.000
14:55043957:G:T	G306C	1.000
14:55043958:G:A	G306D	1.000
14:55043958:G:T	G306V	1.000
14:55043963:T:C	F308L	1.000
14:55043964:T:C	F308S	1.000
14:55043965:T:A	F308L	1.000
14:55043965:T:G	F308L	1.000
14:55043967:T:C	L309S	1.000
14:55043970:T:A	L310H	1.000
14:55043970:T:C	L310P	1.000
14:55043972:C:G	R311G	1.000
14:55043973:G:C	R311P	1.000

dbSNP variants (sampled 300 via entrez): RS1000072326 (14:55026825 C>T), RS1000144229 (14:55026512 G>C,T), RS1000300283 (14:55033169 T>A), RS1000321054 (14:55028433 T>A), RS1000399804 (14:55039668 C>T), RS1000432630 (14:55039417 G>A), RS1000538590 (14:55026945 AG>A), RS1000562918 (14:55031993 T>G), RS1000651794 (14:55027141 A>C,G), RS1000766251 (14:55034423 A>G), RS1000912411 (14:55039342 G>T), RS1001276090 (14:55044595 G>A,C,T), RS1001288806 (14:55026370 G>A), RS1001300780 (14:55046228 G>A), RS1001360972 (14:55026185 C>T)

Disease associations

OMIM: gene MIM:616337 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
autoimmune disease	Limited	Autosomal dominant

Mondo (1): autoimmune disease (MONDO:0007179)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001941_16	Ovarian cancer	8.000000e-10
GCST011346_27	Total cholesterol levels	5.000000e-09
GCST011347_47	Low density lipoprotein cholesterol levels	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004574	total cholesterol measurement
EFO:0004611	low density lipoprotein cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001327	Autoimmune Diseases	C20.111

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methylmercuric chloride	decreases expression, increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
trichostatin A	decreases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
avobenzone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
cylindrospermopsin	increases expression	1
CGP 52608	affects binding, increases reaction	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Glyphosate	decreases expression	1
Acrolein	increases abundance, affects cotreatment, increases oxidation	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Arbutin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	increases abundance, affects cotreatment, increases oxidation	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	increases expression	1
Xylitol	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Cellosaurus cell lines

6 cell lines: 4 cancer cell line, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2H1	Abcam HeLa SOCS4 KO	Cancer cell line	Female
CVCL_D8B5	Ubigene A-549 SOCS4 KO	Cancer cell line	Male
CVCL_D8EP	Ubigene BEAS-2B SOCS4 KO	Transformed cell line	Male
CVCL_D8VW	Ubigene HCT 116 SOCS4 KO	Cancer cell line	Male
CVCL_D9SJ	Ubigene HEK293 SOCS4 KO	Transformed cell line	Female
CVCL_E0PK	Ubigene HeLa SOCS4 KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001658	PHASE4	COMPLETED	Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
NCT00820469	PHASE4	COMPLETED	Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
NCT00862693	PHASE4	UNKNOWN	Calcitriol in the Treatment of Immunoglobulin A Nephropathy
NCT01065285	PHASE4	COMPLETED	Vaccination Against Influenza in Autoimmune Diseases
NCT04015596	PHASE4	TERMINATED	Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS
NCT04127747	PHASE4	UNKNOWN	Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus
NCT04297592	PHASE4	ENROLLING_BY_INVITATION	Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
NCT06499233	PHASE4	RECRUITING	Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
NCT06723548	PHASE4	NOT_YET_RECRUITING	Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
NCT06964269	PHASE4	RECRUITING	Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
NCT00001768	PHASE3	COMPLETED	Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
NCT00035308	PHASE3	COMPLETED	Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
NCT00351377	PHASE3	COMPLETED	Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
NCT00419419	PHASE3	COMPLETED	Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud’s Phenomenon
NCT01004432	PHASE3	COMPLETED	Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
NCT01196091	PHASE3	COMPLETED	A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01205438	PHASE3	COMPLETED	A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01210716	PHASE3	COMPLETED	Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
NCT01281969	PHASE3	COMPLETED	Intravenous Immunoglobulin for PANDAS
NCT01488708	PHASE3	TERMINATED	On Open-Label Study in Participants With Systemic Lupus Erythematosus
NCT01601028	PHASE3	COMPLETED	Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren’s Syndrome
NCT02263703	PHASE3	COMPLETED	Immunogenicity of HPV Vaccine in Immunosuppressed Children
NCT03790293	PHASE3	COMPLETED	Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the RITUXIMAB 3 Trial
NCT05069714	PHASE3	COMPLETED	One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.
NCT00010387	PHASE2	COMPLETED	Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
NCT00716066	PHASE2	ACTIVE_NOT_RECRUITING	Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
NCT00977977	PHASE2	RECRUITING	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT01579110	PHASE2	UNKNOWN	Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.
NCT01778348	PHASE2	COMPLETED	Closing the Loop in Children and Adolescents With Type 1 Diabetes in the Home Setting
NCT02203682	PHASE2	UNKNOWN	Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
NCT02458196	PHASE2	UNKNOWN	Study of Treatment Response on IgG4 Related Disease (IgG4RD)
NCT02647866	PHASE2	COMPLETED	Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
NCT02682511	PHASE2	ACTIVE_NOT_RECRUITING	Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
NCT03183869	PHASE2	TERMINATED	Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
NCT03239600	PHASE2	WITHDRAWN	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren’s Syndrome (pSS)
NCT03345004	PHASE2	COMPLETED	Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
NCT03644069	PHASE2	UNKNOWN	A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)
NCT03651518	PHASE2	COMPLETED	Personalized Therapies in Inflammatory Complex Disease
NCT04186871	PHASE2	COMPLETED	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren’s Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04663204	PHASE2	ACTIVE_NOT_RECRUITING	A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy